July 2017 Volume 13, Issue 7
Volume 13, Issue 7 | July 2017
July 2017
In this Issue
Research & Development
New options against HIV
TSRI shares success in viral research and vaccine developmentHope on the horizon
Public-private partnership teams up for trauma-related brain disordersBringing the data for precision medicine
IBM and tranSMART bring tech together for translational work; tranSMART announces merger with i2b2OSE teams with Memorial Sloan Kettering
Multiyear research collaboration focused on cytotoxic monoclonal antibody OSE-703Preclinical
Repurposing research
NCATS and UNR researchers use compound for experimental cancer therapy to treat muscular dystrophyA contender against AML
Partner organizations present preclinical data supporting superiority of CG’806 to fight AMLIsarna eyes glaucoma and AMD/DME treatment potential
Preclinical results, clinical data support further exploration of ISTH0036 in several ophthalmic indicationsNovel antibody drug class could mean faster arrival of immunotherapies
Nature Medicine reports elimination of large tumors in mice by messenger rna-encoded bispecific antibodiesFeature
Special Focus on Cancer Research News: A glance back and a gaze forward on glyco
Looking at glycobiology with relation to cancer, plus more in recent oncology R&D newsShow Preview: Immuno-Oncology Summit--Exploring the next generation of IO
Immuno-Oncology Summit looks at how to apply new science and technology in developing effective and safe immunotherapiesEditor's Focus
Preclinical perils and clinical catastrophe
Human-relevant non-animal models are becoming ever more relevant and ever more advanced (and thus need more attention from FDA), but they won't prevent or probably much reduce clinical trial mortality, and it's not clear that they will (or should) completely replace animal modelsCommentary
Out of order: A word about communication
In the vein of 'garbage in, garbage out' from the computer programming world, perhaps we also need to think in terms of 'jargon in, gibberish out' a bit more often with scientific discussionsGuest Commentary: Planning successful oncology trials amid a rapidly shifting treatment landscape
When it comes to oncology clinical trials, drug developers need to stay abreast of the rapidly evolving and competitive landscape while also remaining flexible and innovative in responding to these changesBusiness & Government Policy
BIO 2017 wrap-up
A quick look at the recent BIO International Convention and what the event offers to attendeesIt’s all about timing
Supreme Court rules that market announcements for biosimilars can come before approval in Sandoz v. AmgenEMA shares meeting highlights
Focus was on Brexit preparations and development of the EU clinical trial portal and databaseOn the cutting edge
A roundup of instrumentation, software and other tools and technology newsMoving fusion proteins forward
Selexis announces commercial license agreement with Takeda for the development of fusion proteinsDiagnostics
PEPperPRINT and PROGEN to develop novel RA test
SeroRA antigen library will reportedly enable superior rheumatoid arthritis biomarker screeningReading tea leaves? No, reading stools
Research by UC San Diego, Human Longevity and JCVI finds stool microbes predict advanced liver diseasePositive results for PromarkerD
Proteomics International says new blood test can detect diabetic kidney disease earlier than any other methodDiscovery
Trying to gain on glioblastoma
Sweden’s Beactica and Uppsala University launch research to find a way to treat and beat brain cancerExscientia and Sanofi get specific with €250M deal
Companies enter into collaboration aimed at developing bispecific small-molecule drugs‘Artificial’ discovery
BioXcel creates new artificial intelligence company to power biotech and pharma R&DAllergen breakthrough marks 50th anniversary
Thermo Fisher Scientific celebrates the discovery of the immunoglobulin antibody, which triggered five decades of innovation in allergy and asthma diagnosis and treatmentClinical Trials
Recruitment in practice
With a eye on general practitioners, Interface Clinical Research looks to reduce patient dropout rates and rescue failed trialsNovo Nordisk unveils Tresiba results
Diabetes therapeutic reportedly superior to insulin glargine in reducing hypoglycemia, without raising cardiovascular riskOmniComm expands global reach with new deals
TrialOne system to standardize clinical development programs, ensure regulatory compliance and bring greater operational efficiencyGood news regarding diabetes and high cholesterol
Sanofi and Regeneron announce positive results from first dedicated studies evaluating Praluent in individuals with diabetes and hypercholesterolemiaContract Services
CRO consolidation
International CRO acquisition deals popular in Q2Streamlining drug discovery
Dotmatics informatics services expected to aid integrated research capabilities at Domainex
